Learn about the science behind a new standard of precision heart care.
In our eighth Transforming Cardiac Care webinar, we discuss the upcoming, landmark TRANSFORM randomized controlled trial that uses Cleerly’s AI-powered CCTA analysis. The study chair, Dr. Deepak L. Bhatt of Mount Sinai Fuster Heart Hospital, joins Cleerly’s clinical leaders to discuss and answer questions about the study’s goal of demonstrating that a highly personalized care strategy, empowered by AI identification of a patient’s coronary artery disease (CAD) stage, can outperform traditional risk factor management and even prevent cardiovascular events.
Director, Mount Sinai Fuster Heart Hospital
Chief Executive Officer,
Cleerly Inc.
Chief Medical Officer,
Cleerly Inc.
Chief Scientific Officer,
Cleerly Inc.
In our seventh Transforming Cardiac Care webinar, we examined the conventional approaches to evaluating heart disease risk factors, such as cholesterol levels, and their limitations when determining heart health.
Director of Education and Clinical Excellence,
MDVIP
Chief Executive Officer,
Cleerly Inc.
Chief Medical Officer,
Cleerly Inc.
In our sixth Transforming Cardiac Care webinar, we compare coronary artery calcium (CAC) scoring with computed tomography angiography (CCTA) enabled by artificial intelligence (AI).
CEO and Founder of The Agatston Center for Preventive Medicine
Creator of the Agatston Score
Chief Executive Officer,
Cleerly Inc.
Chief Medical Officer,
Cleerly Inc.
Our fifth webinar is a discussion about the emergence of CCTA as a more effective approach to heart attack prevention. When enabled by artificial intelligence, and supported by the right training, equipment, and protocols, non-invasive CCTA offers a level of clinical efficacy that outperforms SPECT and other gold standards currently used to evaluate CAD.
Associate Professor of Medicine and Radiology,
University of Pittsburgh
Chief Executive Officer,
Cleerly Inc.
Chief Medical Officer,
Cleerly Inc.
Join us for our fourth webinar in our Transforming Cardiac Care series for a discussion about new evidence showing that AI-enabled coronary computed tomography angiography (CCTA) has a higher diagnostic accuracy for detecting coronary artery disease (CAD).
Associate Professor of Medicine and Radiology,
George Washington University
Chief Executive Officer,
Cleerly Inc.
Chief Medical Officer,
Cleerly Inc.
Learn how CCTA is used by providers in assessing coronary artery disease to inform individualized treatment.
Preventive Cardiologist and Professor of Medicine,
David Geffen School of Medicine
Chief Executive Officer,
Cleerly Inc.
Chief Medical Officer,
Cleerly Inc.
Learn about the field’s first novel, four-tiered atherosclerotic plaque staging system proposed by Cleerly — the different stages, clinical utility and implementation.
Director of Cardiovascular Prevention and Wellness,
National Jewish Health
Chief Executive Officer,
Cleerly Inc.
Chief Medical Officer,
Cleerly Inc.
Our panelists discussed a highly promising, clinically proven new standard of heart care and AI-driven digital technology that allows physicians to more accurately measure disease, provide treatment and prevent future heart attacks.
Assistant Professor of Cardiovascular Disease,
University of Milan
Chief Executive Officer,
Cleerly Inc.
Chief Medical Officer,
Cleerly Inc.
